Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome

IMCIVREE expected to be funded and available for use in England and Wales within three months through the National Health Service in specialist centresBOSTON, May 22, 2024 -- Rhythm...

Related Keywords

United Kingdom ,United States ,Boston ,Massachusetts ,Northern Ireland ,Craigavon ,Yann Mazabraud ,David Connolly ,Philip Beales ,Adam Daley ,Rhythm Pharmaceuticals ,Healthcare Products Regulatory Agency ,Scottish Medicines Consortium ,Institute Of Child Health ,Head Of International At Rhythm Pharmaceuticals ,Corporate Communications ,Rhythm Pharmaceuticals Inc ,National Institute For Health ,European Union ,Drug Administration ,National Health Service ,European Commission ,Medicines Healthcare Products Regulatory Agency ,Berry Company Public Relations ,Nasdaq ,Exchange Commission ,National Institute ,Care Excellence ,Executive Vice President ,Ormond Street Institute ,European Marketing Authorization ,Highly Specialised Technologies ,Pre Existing Nevi ,Sexual Arousal ,Suicidal Ideation ,Serious Adverse Reactions Due ,Benzyl Alcohol Preservative ,Low Birth Weight Infants ,Yellow Card Scheme ,Product Characteristics ,Prescribing Information ,Important Safety ,Private Securities Litigation Reform Act ,Quarterly Report ,Investor Relations ,